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Abstract  
Radiofrequency ablation (RFA) is an effective local treatment for curative intent in 
patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter   
< 3 cm. Several meta-analyses have shown that RFA and surgical resection are 
comparable in terms of their impact on overall survival.  The only clinical data available 
on markers that are predictive of recurrence and survival after RFA treatment are based 
on retrospective observational studies.  Prospective randomized trials are thus needed to 
further research in this area. 
In the present review we analyzed a number of clinical factors that are considered to 
predict recurrence or survival in HCC patients treated with RFA.  We also discussed in 
detail the circulating biomarkers investigated to date, together with their potential to 
predict prognosis and recurrence after RFA therapy. 
Overall survival rates of patients with HCC are significantly affected by liver function, 
defined as Child-Pugh class, high baseline serum alpha-fetoprotein levels, and the 
presence of portosystemic collaterals.  However, the development of local tumor 
progression does not significantly affect overall survival. This result is achieved by the 
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effective therapies in patients who relapse after treatment with RFA.  For this reason 
there is an urgent need to identify new circulating biomarkers.   
 
Keywords  
Clinical outcome, radiofrequency ablation, hepatocellular carcinoma, alpha-fetoprotein, 
microRNAs, PD-L1, nivolumab, tremelimumab, immunotherapy, circulating miRNAs. 
 
1. Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide 1. 
Traditionally, hepatic resection and transplantation are considered the treatments of 
choice for patient care and have led to great improvements in morbidity, mortality and 
long-term survival 2. However, radiofrequency ablation (RFA) is emerging as an 
effective local treatment for curative intent in patients with cirrhosis of the liver and 
HCC with a diameter < 3 cm  3 4. Several meta-analyses  5–7 have shown  that RFA and 
surgical resection have a comparable impact on overall (OS) and recurrence-free 
survival (PFS) when patients have Child-Pugh class A liver function and a lesion       < 
3 cm 8. 
RFA is also used as bridge to liver transplantation, as reported by Lu et al. 9 and 
Mazzaferro et al. who demonstrated the effectiveness of this clinical approach in two 
large case series with very low dropout rates (6% and 0%, respectively) 10.The majority 
of recurrences are distant rather than local. Although several studies have been carried 
out to identify biomarkers that could be used to predict cancer recurrence, specific 
pathological patterns remain to be explored.  
2. Clinical factors of RFA survival 
AC
CE
PT
ED
 M
AN
US
CR
IPT
4 
 
There are still no prospective randomized studies evaluating clinical factors that are 
potentially predictive of recurrence and survival after RFA treatment, and findings 
published to date are based on retrospective observational studies.  As shown in Table 
1, various factors have been considered to predict survival in HCC patients treated with 
RFA. 
With regard to liver function, patients with Child-Pugh B disease  11–14 have an 
increased risk of death compared to those with Child-Pugh A 3,15–21. The relative risk 
between Child Pugh B and A has been reported as around 2.26 and 5.39, respectively 
15,18.  The severity of the underlying liver disease may also represent a risk factor for 
HCC development and recurrence, highlighting the role of liver function in 
hepatocarcinogenesis. Interestingly, N’Kontchou et al. reported that the response to 
antiviral treatment in patients with hepatitis C virus (HCV)-derived cirrhosis, which 
resulted in the restoral of normal hepatic function, was associated with a dramatic 
decrease in HCC recurrence and a higher survival rate. In a group of 35 HCC patients 
with HCV-derived cirrhosis given antiviral therapy, only 10 obtained a viral response. 
All patient that achieved a complete response after RFA treatment had without tumor 
recurrence.3 
With regard to liver function, other factors of poorer prognosis include reduced albumin 
values  3,15,16,22–25, increased bilirubin levels 3,22,25,26, and portal hypertension 15–17,26. 
However, data reported are somewhat contradictory  3,13–17,19,21–29, probably due to  
different methods of patient enrollment in the various studies. In particular, when lesion 
size is considered as a continuous variable, there is often no evidence of a poorer 
prognosis if size increases. In studies in which lesion size was dichotomized over 2 cm, 
results were positive, confirming that RFA is less effective for lesions > 3 cm. 
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The percentage of patients with non-solitary nodules treated in the various studies is an 
important factor.  From an analysis of negative studies 14,15,19,23,25,29, it emerges that  
about 15% of enrolled patients had multiple lesions, whereas a higher number of 
patients with multiple nodules were recruited (> 20%) showing positive results in 
univariate analyses  3,13,16,17,22,24,30.   
 Concerning local tumor progression, with the exception of  N'Kontchou’s study 3 where 
the hazard ratio (HR) was 0.53, patients enrolled in various studies with local tumor 
progression all had a poorer prognosis 3,12,15,16.  These findings are undoubtedly 
correlated with radiofrequency rescue therapies which have a strong impact on survival 
(orthotopic liver transplantation, surgery, transarterial chemoembolization [TACE]), but 
are also linked to systemic therapies).  Finally, parameters such as sex 3,11–19,21–24,27–30 
and hepatitis B virus (HBV) 19,22,24–26,31 or hepatitis C virus (HCV) 21,22,25,26 positivity do 
not seem to affect post-RFA survival. Moreover, as elucidated above, the response to 
antiviral treatments led to a lower recurrence rate and better survival. 
3. Clinical factors of RFA recurrence 
As previously mentioned, there are still no randomized clinical trials that have evaluated 
and validated clinical factors potentially predictive of post-RFA recurrence.  Starting 
from the analysis of various studies (Table 2), the size and number of lesions are crucial 
parameters for predicting recurrence in the majority of cases, in contrast to what is 
reported for survival. This is attributable to the fact that, when more than one tumor is 
observed in the liver, intrahepatic metastases or multicentric HCC are more likely to 
occur. The few negative studies that considered these 2 parameters had patients with 
early-stage disease or solitary tumors. In fact, the median tumor size was around 2 cm at 
baseline. In this patient setting, RFA represents a promising strategy to control local 
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disease. Parameters such as sex and HBV or HCV positivity do not seem to affect post-
treatment recurrence.  
 
4. Circulating biomarkers of RFA recurrence 
Several investigations have been carried out to identify which biomarkers markers could 
be useful to predict cancer recurrence, but specific pathological patterns have yet to be 
elucidated. We will now focus on the circulating biomarkers investigated to date and 
discuss their potential to predict HCC prognosis and recurrence after RFA therapy. As 
shown in Table 3, various factors have been considered. 
 
5. Alpha-fetoprotein, Des-γ-carboxy prothrombin and Lens culinaris 
agglutinin-reactive fraction of alpha-fetoprotein 
Alpha-fetoprotein (AFP) was one of the first markers to be investigated for the 
diagnosis and prognosis of HCC and is still widely used in clinical practice because it is 
a simple and inexpensive test. However, given that AFP also has a clinical significance 
in patients with non-cancerous hepatic disorders, such as chronic hepatitis, cirrhosis or 
massive hepatic necrosis, 32–34 it is not considered to be a completely reliable marker for 
HCC diagnosis.  Conversely, it is believed to be predictive of  HCC recurrence 35–37 .  In 
a study by Siripongsakun et al., AFP levels in the pre-RFA sera of 146 patients were 
tested as a diagnostic tool using the same cutoff as that used to predict HCC recurrence 
(20 ng/mL), revealing a sensitivity of 72.2% and a specificity of 56% 38.  Considering 
modified criteria of AFP ≥100ng/mL and alanine aminotransferase ≥40 U/L, sensitivity 
in detecting recurrence reached 100%, with a specificity of 85%.  In this setting, the role 
of AFP as a circulating biomarker of HCC recurrence after RFA treatment has been 
investigated, showing conflicting results. Pre- and post-RFA serum levels of AFP were 
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assessed in a large case series of HCC patients undergoing RFA, demonstrating a 
significant association between low circulating amounts of AFP (≤20 ng/mL) and time 
to recurrence (HR: 1.995; 95% CI, 1.476-2.697), but not a significant benefit in OS39.  
In another study, AFP levels ≥ 20 ng/mL proved to be a prognostic factor of early 
recurrence, within 6 months after treatment (HR: 3.02; 95% CI, 1.69–5.38), while an 
AFP level <20 ng/mL was a marker of favorable OS (HR: 2.90; 95% CI, 1.47–5.74) in 
patients undergoing RFA after TACE failure 40. Moreover, a decrease of >20% in AFP 
serum levels after RFA therapy strongly influenced the 5-year survival rate and tumor 
recurrence in a subgroup of patients with pre-treatment serum levels of AFP ≥100 
ng/mL 41. 
Conversely, AFP baseline sera levels did not distinguish between 98 HCC patients who 
relapsed after RFA treatment and those who did not 42. Furthermore, another study did 
not observe a significant correlation between AFP serum levels and short-term outcome 
despite a sharp decrease in this marker after RFA therapy 43. The role of AFP in 
evaluating recurrence after RFA is still subject to debate and at present there are no 
indications to perform it systematically. Randomized studies are needed to evaluate the 
real predictive role of AFP.  
Des-γ-carboxy prothrombin (DCP) is a form of prothrombin produced by cancerous 
hepatocytes 44. As the protein is linked to neoangiogenesis, it is thought to play a role in 
HCC recurrence. In a case series of 1057 patients treated with RFA, DCP levels >200 
mAu/mL proved to be the strongest indicator of vascular invasion at the 1-, 3-, 5-year 
follow-up (HR: 3.24, 95% CI, 1.90–5.51 ) 45. In another study on 10-year outcome after 
RFA, DCP serum levels >400 mAu/mL were found to be an independent factor related 
to tumor local progression 46.  Of note, a recent study identified pre-ablation serum DCP 
levels ≥40 mAu/mL as an independent risk factor for OS, while the same levels post-
AC
CE
PT
ED
 M
AN
US
CR
I T
8 
 
ablation were a risk factor for both OS (HR: 3.438; 95% CI, 1.331-8.877) and DFS 
(HR: 4.934; 95% CI, 2.76-8.81) 39. Another study found that pre-treatment DCP serum 
levels ≥40mAu/mL were predictors of time to recurrence, as were serum levels of AFP 
≥50 ng/mL and a prothrombin time of <70% 47. These data were later confirmed in 
other studies in which pre-treatment DCP serum levels <100AU/mL were identified as 
predictors of prolonged OS (HR: 5.49; 95% CI, 2.23-13.5) time to recurrence (HR: 
6.82; 95% CI,  3.49-13.3) 48. 
Lens culinaris agglutin-reactive fraction of AFP (AFP-L3) is a fucosylated isoform of 
AFP with higher binding affinity to lectin Lens culinaris agglutinin 49. It is still not used 
in clinical practice, even though it has been shown to improve sensitivity and specificity 
of diagnostic tools when used  in combination with AFP and DCP 50. 
With regard to HCC recurrence after RFA treatment, an AFP-L3 serum level >15% 
both pre- and 2 months post-RFA was a strong indicator of tumor recurrence                    
(HR: 4.25; 95% CI, 1.42–12.74), while pre-ablation and post-ablation levels of >15% 
and ≤15%, respectively, were not 51.  Another study comparing the clinical values of 
AFP-L3, AFP and DCP in the serum of 124 patients undergoing RFA showed that AFP-
L3 was the most reliable marker for OS and time to recurrence 52. Serum levels of      
AFP-L3>10% prior to RFA therapy have also proven to be an independent risk factor 
for local tumor progression and OS after RFA (HR: 2.94; 95% CI, 1.09–7.94) 53. Ueno 
et al. found that high levels (>20 ng/mL) of pre-RFA AFP serum levels were predictive 
of poorer OS in 160 patients undergoing RFA, but only in association with high levels 
of Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxy 
prothrombin (DCP) (OR: 1.78; 95% CI, 1.16-2.72) 54, casting doubt on the accuracy of 
previous data that showed a significant association between AFP-L3 ≥10% and lower 
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recurrence-free survival, but not between AFP and recurrence or between the three 
markers and recurrence 55. 
AFP, AFP-L3 and DCP are the most widely investigated circulating biomarkers in 
hepatocellular carcinoma and have been shown to be correlated with diagnosis and 
clinical outcome. Conversely, these markers have not proven very reliable in predicting 
recurrence after treatment for HCC, in particular RFA. Of the 3, DCP has the greatest 
predictive potential, but still lacks validation and an objective cut-off value.   
 
6. Immune response biomarkers 
Radiofrequency is recognized as an acute inflammation-inducing treatment because it 
directly destroys tumor cells, resulting in a release of tumor-associated  neo-antigens 
(TAA). In fact, an increase in circulating markers such as histones, myeloperoxidase 
(MPO), inflammatory cytokines (IL-1β, IL-6, IL-10, TNF-α), and markers of liver 
damage such as ALT and AST have been found in the plasma of patients 24 hours post-
RFA 56,57. In this setting, several immune response markers have been investigated as 
potential prognostic tools. Given the role of heat shock proteins (HSPs) in chaperoning 
tumor peptides, this class of proteins are known to have an adjuvant effect and to act as 
an alarm for anti-tumor T cell-mediated immunity. In a study of patients with different 
malignancies including HCC, pre- and post-RFA serum levels of heat-shock protein-70 
(HSP70) were analyzed and correlated with outcome.  An increase in HSP70 levels was 
transiently detectable one day after RFA treatment, and patients with a ≥2-fold increase 
in HSP70 had better clinical outcome, possibly due to the immune response activated 
through the tumor peptides carried by HSPs 58. 
An ex-vivo study investigated TAA T-lymphocyte response after RFA treatment, 
detecting them in 62.3% of analyzed patients. The number of TAA-specific T-cells 
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post-ablation was correlated with RFS, whereas those pre-ablation were not 59. The 
aspartate aminotransferase-to-platelet ratio index (APRI) >1.38 was  
recently identified as an independent risk factor for tumor recurrence after RFA 
treatment (HR: 2.64, CI 95%, 1.488–4.714) 42, while a baseline neutrophil-to-
lymphocyte ratio (NLR) > 2.4 was previously associated with poorer OS but was not 
significantly related to relapse. In contrast, NLR > 2.4 post-RFA was found to be 
predictive of both OS and time to recurrence 19. Moreover, an activated phenotype of 
NK cells was detected in the blood of patients after RFA, with a higher secretion of 
interferon-γ (IFNγ). Interestingly, when patients were divided into two subgroups, i.e. 
high vs. low IFNγ production and cytotoxicity, both parameters were associated with 
disease-free survival 60. These data suggest that the immune system response to RFA 
treatment and tumor-derived neo-antigens may be predictive of recurrence after RFA 
treatment. 
Of note, a recent study associated an increase in plasma C-X-C motif chemokine 10 
(CXCL10) with earlier recurrence of HCC, finding a significant correlation between 
time of recurrence and CXCL10 plasma levels at baseline, 1 and 7 days after RFA61. C-
reactive protein (CRP), a marker of systemic inflammation related to various diseases 
including HCC, has also been investigated, Fujiwara et al. observing that patients with 
CRP pre-treatment circulating levels >0.08mg/dL had early recurrence after RFA and 
worse OS with respect to patients with CRP circulating levels >0.08mg/dL 62. 
A study by Shi et al. evaluated the expression of programmed-death ligand 1 (PD-L1) in 
patients with liver metastasis from colorectal cancer (CRCLM) before and after RFA 
treatment prior to surgery. The authors confirmed an increased T-cell infiltration in the 
tumor microenvironment of patients who underwent RFA compared to those who did 
not, with a higher CD8/CD4 ratio. Interestingly, they also found increased levels in PD-
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L1 expression in both cancer cells and immune cells associated with RFA with respect 
to the tumor microenvironment of the non-RFA group. In particular, a comparison 
between pre- and post-ablation levels of PD-L1 in RFA patients revealed an increase in 
the expression of the protein in cancer cells and immune cells that was correlated with 
the ablation therapy 63. PD-L1 expression has been shown to be predictive of response 
to anti-PD1 antibodies 64 and a phase I/II study  highlighted durable responses and good 
safety profiles of anti-PD-1 Nivolumab monotherapy in HCC patients, including those 
with HBV and HCV 65. A pilot study explored the safety and feasibility of 
Tremelimumab in combination with locoregional therapies aimed at promoting 
immunogenic tumor cell death in 18 patients (8 underwent TACE and 10 RFA) with 
advanced-stage HCC after refractoriness/intolerance to sorafenib. This combined 
therapy proved safe and, of the 10 patients evaluable for response outside of TACE or 
RFA treated lesions, 4 achieved confirmed partial objective response and post-treatment 
tumor biopsies showed immune cell infiltration in all evaluable patients. 66 To date, 
several trials testing safety and efficacy of immunotherapy are ongoing in advanced 
disease, and we think that in the future, immunotherapy can be a useful treatment in 
patients underwent RFA (NCT03383458). 
Another study investigated clinical response in 62 HCC patients treated with RFA 
followed by cellular immunotherapy or RFA alone, reporting significant benefits in 
time to recurrence,  OS and risk of local tumor progression (HR=0.136; 95% CI, 0.049–
0.379) in the group that underwent the combined therapy 67. Given that tumor cells are 
capable of immunomodulating the tumor microenvironment, and that RFA is an 
immune-related treatment, it might be useful to investigate the role of immune targeted-
therapy as an adjuvant to RFA. In fact, apart from local inflammation, RFA results in a 
release of neo-TAAs into the blood circulation that are recognized by antigen-
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presenting cells (APC) and presented in secondary lymphoid organs through major 
histocompatibility complexes to cytotoxic T lymphocytes for priming and activation. 
Activated tumor-specific CTLs recognize and attack tumor cells, enhancing the anti-
tumor action of RFA (Fig.1).  In this setting, combining these therapeutic approaches 
could enhance the immune response against tumor neo-antigens, blocking the 
mechanism of tumor immune-editing to obtain  a restored and continuous action of the 
cancer-immunity cycle 68. 
 
7. microRNAs 
Interesting research has been carried out into microRNAs (miRNAs), small non-coding 
RNAs involved in several physiological and pathological patterns, including 
carcinogenesis. Several studies have identified tissue and/or circulating miRNAs for 
HCC diagnosis, prognosis and recurrence after locoregional treatment 69–72. Conversely, 
few significant results are available on the relation between miRNAs and HCC 
recurrence after RFA treatment. Plasmatic expression of miR-122 (>100) prior to RFA 
was associated with poorer OS  in a cohort of 57 HCC patients 73, while low plasmatic 
levels of mir26a and 29a were correlated with worse DFS (HR=1.72; 95% CI, 1.04–
2.83 and HR=1.75; 95% CI, 1.04–2.94, respectively) in patients treated with surgical 
resection or RFA 74. 
Epithelial-to-mesenchymal transition (EMT) has also been proposed as a resistance 
mechanism in HCC recurrence. Low expression levels of 200c and miR34a were found 
in bioptic tissue samples of 10 HCC patients who relapsed after RFA compared to 78 
who did not undergo RFA, suggesting that EMT-related markers might be useful to 
predict poorer prognosis and aggressive local recurrence after RFA treatment 75.  
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Moreover, a fascinating scenario is that involving the miRNAs as therapeutic targets; 
miRNA-based therapy takes advantege of  two main strategies: the use of miRNA 
antagonists (antagomiR or antimiR) to block oncogenic miRNAs, or miRNA 
replacement, to restore lost function of oncosuppressor miRNAs 76. For example, the 
therapeutic potential of miR-122, miR26a and miR-124 has been developed in mice, 
and there is a need to further investigate their potential role as miRNA mimics 77. 
Several tissue miRNA profiles have been evaluated in relation to tumorigenesis, cancer 
development and metastasis 78. Disrupting the tumor cells, RFA treatment renders 
evaluable tissue biomarkers at circulating level, and given the rising importance of 
miRNAs in HCC therapeutics, finding and targeting such biomarkers in the blood 
circulation to predict recurrence could be very important in the management of disease. 
Given the acknowledged role of miRNAs in HCC diagnosis and prognosis, it would 
seem logical to evaluate their potential as a prognostic and therapeutic tool to predict 
recurrence after RFA. 
 
8. Other studied biomarkers 
A study by Ma et al. focused on γ-glutamyltranspeptidase (GGT), an enzyme related to 
extracellular oxidative stress, high circulating levels of which are usually found in HCC 
patients. Results showed that elevated serum GGT levels before RFA treatment 
correlated with worse OS and time to recurrence when compared with normal serum 
GGT levels 79.  Furthermore, pre-RFA levels of serum ferritin <244 ng/mL, a marker of 
iron accumulation and consequent hepatic damage and carcinogenesis, were found to be 
predictive of  better OS and longer time to recurrence 18. Although serum levels of 
vascular endothelial growth factor (VEGF) have not shown increased levels when 
measured at baseline, 2 or 5 days after radiofrequency ablation 80, pre-RFA circulating 
AC
CE
PT
ED
 M
AN
US
CR
IPT
14 
 
VEGF levels >240 pg/mL have been found to be associated with worse OS in HCC 
patients and time to recurrence 81. In this setting, further research into angiogenic factors 
as predictors of post-RFA recurrence are warranted given that RFA exhibits a lower 
angiogenic effect than TACE 82. 
 
9. Uninvestigated potential biomarkers 
To date, no studies have been carried out about the potential of long non-coding RNAs 
(lncRNAs) to predict recurrence after RFA treatment. It could be interesting to test these 
markers in patients undergoing RFA treatment, given that the dysregulation of many 
circulating lncRNAs have been correlated with HCC onset and development. For 
example, HULC (highly upregulated in liver cancer) has been found up-regulated in 
liver cancer tissues compared to non-cancerous tissues 83; high expression of HOTAIR 
(HOX transcript antisense RNA) has been correlated with poorer prognosis and disease 
recurrence after surgery 84 in HCC patients and MALAT1 (metastasis-associated lung 
adenocarcinoma transcript 1) has been related to cell proliferation and migration, and it 
has been described as a potential diagnostic and prognostic biomarker for HCC patients 
85,86.  
Moreover, there is a growing interest about the role of circulating microvescicles, that 
contain a plethora of biomarkers that could be potentially useful in cancer diagnosis, 
prognosis and therapeutic monitoring. Protected by the vescicle membrane, and less 
exposed to RNAses, intravescicular miRNAs and RNAs are more stable than circulating 
miRNAs and coding RNAs themselves, and, as a consequence, more reliable markers. 
For what concerns HCC, most of studies focused on the transcriptome of the exosomes, 
a particular class of microvescicles, underlying the clinical significance of several 
miRNAs 87,88. In this setting, it could be useful to investigate the potential of circulating 
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microvescicles as a non-invasive tool to test new biomarkers in monitoring response to 
therapy and in predicting disease recurrence after RFA treatment. Techniques such as 
massive parallel sequencing for RNA (RNASeq) could be very useful to this aim. 
As a non-invasive and low cost tool, the approach of metabolomic could be an 
intriguing research field. As most of compounds pass through the liver after intestine 
absorption, this organ is a key regulator of many circulating metabolites, empowering 
the possibility to relate their serum levels to liver physiopathology. The small bio-
compounds (usually <1kDa molecules) profiles in chronic liver diseases including HCC 
have been investigated by NMR , but still there are no biomarkers able to predict time to 
recurrence after locoregional treatments that could be translated to clinical practice 89. 
The same potential could be expected by proteomics approaches, e.g. mass spectrometry 
(MS), useful in identifying new circulating biomarkers related to liver physiopathology. 
Most of studies in HCC highlighted proteomic plasmatic and serum signatures of  
pathways related to immunity, iron metabolism and homeostasis, apoptosis and cell 
degeneration/regeneration 90. These biomarkers profiles could be used in combination to 
AFP, AFP-L3 and DCP to empower the sensitivity in monitoring tumor progression and 
recurrence after RFA treatment. 
In the field of liquid biopsy, increasing interest is focusing on circulating DNA 
(ctDNA). The analysis of this biomarker could be carried out with two principal aims: 
quantitative evaluation, and qualitative changes. The quantitative analyses evaluate 
changes in ctDNA burden in plasma/serum of patients, and there are data correlating 
ctDNA quantity with poorer prognosis of patient with HCC 91–93. Methylation patterns 
at CpG sites of oncosuppressor genes occurs frequently in HCC, and these qualitative 
changes are the most investigated at a circulating level94,95; in particular, methylation 
status predicts metastastasis or recurrence of disease96 and poor prognosis97. More 
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recent studies are focusing on genome-wide methylation technologies for ctDNA, and a 
study by Wen et al. identified a 4 gene signature for diagnosis of small nodules (<3 
cm)98. It could be important to test this molecular profile to diagnose also early disease 
recurrence. Moreover, it has been proved that presence of ctDNA is predictive for portal 
vein invasion and extra-hepatic metastases in patients undergoing hepatectomy or liver 
transplantation99. Still there are no data on the potential of ctDNA in prediction of 
disease recurrence of patients with HCC after RFA, and this biomarker could be a non-
invasive tool to use in clinical practice to predict prognosis and recurrence in patients 
with HCC treated with RFA. 
 
Conclusions 
In conclusion, RFA is an effective first-line treatment modality for patients with early-
stage HCC, obtaining good overall survival rates. OS is significantly affected by liver 
function, defined as Child-Pugh class, high baseline serum AFP level, and the presence 
of portosystemic collaterals, but not by long-term potentiation does New circulating 
biomarkers are thus urgently needed as non-invasive tools to monitor response to 
treatment and to detect HCC recurrence after RFA treatment.  
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Figure and table Legends 
Fig.1.  Radiofrequency ablation (RFA)-induced release of neo-tumor-associated 
antigens (neo-TAAs) and immune system response.  A)  RFA needle is inserted into the 
tumor mass.  B)  Activation of current generates frictional heating around the electrode.  
C)  Destruction of tumor nodule, with subsequent release of neo-TAAs and tumor 
debris into the local blood circulation where inflammatory infiltrate accumulates 
(macrophages, natural killers, neutrophils and T lymphocytes). D) Neo-TAAs are 
drained to secondary lymphoid organs through afferent lymphatic vessels, stimulating 
immature dendritic cells to activate T cells. E) Activated tumor-specific T-cells enter 
the blood circulation and kill tumor cells. Immune co-stimulators and immune 
checkpoint inhibitors have been proposed as potential adjuvant therapies with curative 
intent  ILs, interleukins.    
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Tables: 
 
Table 1. Graphical aspect on overall survival of HCC patients after RFA. For Material 
and methods show supplementary materials 
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Table 2. Graphical aspect on recurrence free survival of HCC patients after RFA. For 
Material and methods show supplementary materials 
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Table 3. Circulating biomarkers investigated to date for HCC recurrence after RFA  
Circulating 
biomarker 
Category Application RFA recurrence Reference 
AFP 
 
Serum glycoprotein 
 
Diagnosis and prognosis 
 
<20ng/mL post-RFA treatment (P<0.001) 39 
AFP-L3 Serum glycoprotein Diagnosis and prognosis ≥20 ng/mL levels predicted early recurrence (HR 3.02) 
<20ng/mL levels predicted better OS (HR 2.9) 
40 
>100 ng/mL levels reached 100% sensitivity and 85% specificity in predicting 
recurrence 
38 
>20% decrease starting by >100ng/mL pre-RFA treatment associated with 
better DFS and OS 
41 
Pre-treatment levels did not discriminate between recurrent and non-recurrent 
patients  
42 
>20ng/mL levels only predicted OS in association with AFP-L3 and DCP 44 
>15% pre- and post-RFA was an indicator of HCC recurrence (HR 4.25) 48 
 
DCP 
 
Enzyme secreted by  
cancerous hepatocytes 
 
Diagnosis and prognosis 
<40 mAU/mL post-RFA predictor of better OS (P=0.002) and RFS (P<0.001) 39 
More reliable than AFP in predicting DFS and OS 49 
>10% pre-RFA was an indicator of tumor progression and poor survival; HR 
2.94 
50 
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>400 mAU/mL levels were predictors of tumor local progression 53 
 
APRI 
 
Aminotransferase-to-
platelet ratio index 
 
 
≥40 mAU/mL levels were predictors for OS and DFS 39 
≥40 mAU/mL levels were predictive of intrahepatic distant recurrence 
(p=0.006) 
54 
<100 mAU /mL levels were associated with prolonged OS (HR 5.49) and RFS 
(HR 6.82) 
55 
>1.38 was predictive of tumor recurrence (HR 2.64) 42 
NLR Neutrophil-to-
lymphocyte ratio 
Tumor inflammation compared to 
host immunity  
>2.4 was a predictor of  recurrence (p=0.01) and poorer OS (p=0.006) 19 
GGT Serum biomarker Extracellular oxidative stress OS survival (P=0.001) and recurrence (P=0.001) 76 
Ferritin Serum biomarker Iron accumulation and liver 
damage 
<244 ng/mL levels predicted better OS (P<0.001) and a longer time-to-
recurrence (P<0.001) 
18 
miR122 Serum miRNA Related to hepatocarcinogenesis Expression >100 predicted poorer OS (P=0.042) 73 
mir26a, miR29a Serum miRNA Tumor suppressors in 
carcinogenesis and metastasis 
Low expression predicted poorer DFS (HR 1.72, HR 1.75) 74 
miR200c, miR34a Tissue miRNA EMT inhibitors  Low expression associated with relapse (P=0.04) 75 
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HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; HR, hazard ratio; RFS, relapse-free survival; OS, overall survival; DFS, disease-free survival; AFP, alpha-
fetoprotein; AFP-L3: lens culinaris agglutinin-reactive fraction of AFP; DCP: des-γ-carboxy prothrombin; GGT, γ-glutamyl transpeptidase; EMT, epithelial-mesenchymal 
transition 
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